RMC-4998
RMC-4998 is an orally bioavailable inhibitor that selectively targets the active, GTP-bound state of the KRASG12C mutant. By forming a ternary complex with intracellular cyclophilin A (CYPA), it disrupts the ERK signaling pathway to induce apoptosis, making it a valuable tool for investigating KRAS-driven cancers in both in vitro and in vivo research models.
Product Specifications
CAS Number
2642037-07-6
Product Name Alternative
RMC4998
Field of Research
Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
99.11% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (3.36 mM) ; DMSO:80 mg/mL (81.36 mM)
Smiles
O=C (N1CC[C@@]2 (C1) C (N (C (C (C) C) C (NC3C (N4N[C@@H] (CCC4) C (OCC (C) (CC5=C (C6=C ([C@@H] (C) OC) N=CC=C6) N (CC) C7=CC=C (C8=CC (C3) =CC=C8) C=C57) C) =O) =O) =O) CC2) =O) C#CC (C) (C) N (C) C
Molecular Formula
C57H74N8O7
Molecular Weight
983.25
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
OKAG00603 96 Well
CDK1/CDC2 Colorimetric Cell-Based ELISA Kit (OKAG00603)
Sign In for Pricing
View Details 